Piper Sandler analyst Matt O’Brien keeps a Neutral rating and $50 price target on Integra LifeSciences. While the company guided Q4 earnings above the high end of prior guidance range in conjunction with the announcement of a CFO transition, its view that Integra’s end markets are "slow growth" remains unchanged, the firm tells investors in a research note. Piper Sandler further states that while it is positive on the spate of new products coming to market for the company, there are "better names to own" in the mid-cap med-tech universe.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IART:
- Campbell Soup names Carrie Anderson as new CFO
- Integra LifeSciences Reports Select Preliminary Fourth Quarter and Full-Year 2022 Financials
- Integra LifeSciences reiterates plans to initiate $150M share buyback in 2023
- Integra sees FY22 adjusted EPS above $3.29-$3.33 range, consensus $3.30
- Integra LifeSciences sees Q4 revenue $397M-$398M, consensus $397.5M
